Inavolisib for Advanced Endometrial Cancer with PIK3CA Mutations
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital, Women’s health & pregnancy clinical trials.
This trial tests inavolisib, a targeted cancer drug, in women with advanced or recurrent endometrial cancer that has a specific genetic mutation called PIK3CA. The drug is designed to stop cancer cells from growing by blocking a protein pathway that helps tumors survive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced, recurrent, or metastatic endometrial cancer confirmed by biopsy or tissue sample
- Your tumor has a PIK3CA genetic mutation (specific types listed by the trial)
- You have progressed (gotten worse) after platinum-based chemotherapy, with no more than 4 previous chemotherapy treatments
- You have at least one measurable tumor that can be tracked on imaging scans
- You are able to swallow pills and have adequate kidney, liver, and bone marrow function
- You are not pregnant or breastfeeding, and if you can have children, you agree to use reliable birth control during the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
This trial is testing a drug called Inavolisib (a type of targeted therapy) given before surgery for people with early-stage, hormone receptor-positive, HER2-negative breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding Inavolisib to standard endocrine therapy can shrink the tumor more effectively.
This Phase 3 study tests inavolisib plus Phesgo versus placebo plus Phesgo in people whose breast cancer has both HER2-positive and PIK3CA-mutated tumor markers. The goal is to see if adding inavolisib improves how well the treatment controls the cancer and how safe it is.
This trial tests whether a new targeted pill (inavolisib) plus hormone therapy (fulvestrant) can slow or stop breast cancer growth in people whose cancer has a specific genetic change called a PIK3CA mutation. It is for patients whose disease worsened after previous hormone-and-CDK-inhibitor treatment.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.